Linear IgA Disease

  • Diagnosis
  • Algorithms
  • Monitoring
  • Background
  • Lab Tests
  • References
  • Related Topics
  • Videos

Indications for Testing

  • Presence of chronic blistering, urticarial plaques, eczematous skin disease after other more common diseases ruled out

Laboratory Testing

  • Initial serum testing – pemphigoid and pemphigus panels and endomysial antibodies (all 3 tests for initial screening) or epithelial skin antibodies testing
    • Broad testing recommended unless a specific immunobullous skin disease type is suspected
      • IgA antibodies localized to the epidermal side of split skin or showing a combined epidermal-dermal pattern
        • IgA antibodies showing dermal localization alone are rare but do occur
  • Serum IgA basement membrane zone (BMZ) antibodies by indirect immunofluorescence
    • Bind to the epidermal, dermal, or combined epidermal-dermal areas of split skin
    • Positive in 60-70% of patients with linear IgA disease

Histology and Immunohistology

  • Histopathology – bullae are subepidermal with neutrophils along the BMZ and occasionally in dermal papillary tips
  • Perilesional skin biopsy (cutaneous direct immunofluorescence)
    • IgA BMZ antibodies in linear pattern present in 100% of patients
    • Complement and lesser intense linear IgG and/or IgM BMZ staining also may be present 

Differential Diagnosis

  • Epithelial basement membrane zone IgA antibody testing or epithelial skin antibodies to monitor disease activity and response to therapy

Linear IgA disease is a blistering disorder of the skin and mucous membranes.

  • Also known as linear IgA bullous dermatosis (in adults)
  • Also known as chronic bullous disease of childhood (in children)

Epidemiology

  • Prevalence – rare disorder
  • Age
    • Adult – average age of onset >60 years
    • Childhood – birth-10 years (average 4.5 years)
  • Sex – M<F (minimal)

Risk Factors

Pathophysiology

  • Neutrophil involvement – usually greater in linear IgA disease 
  • Eosinophil involvement – usually greater in pemphigoid and epidermolysis bullosa acquisita
  • Serum IgA basement membrane zone (BMZ) antibodies bind to the epidermal, dermal, or combined epidermal-dermal areas of split skin
    • The linear IgA bullous disease antigen of 97 kDa (LABD97) and the 120 kD linear IgA disease antigen-1 (LAD-1) are cleavage products of bullous pemphigoid antigen 2 (BP180) and are major antigenic targets for IgA autoantibodies
    • Type VII collagen IgA antibodies may account for dermal staining on split skin
  • Both IgA and IgG BMZ antibodies may be found in tissue and serum of a subset of patients

Clinical Presentation

  • Papulovesicles, bullae, or urticarial plaques on extensor, central, or flexural sites with truncal involvement
    • May also appear annular or herpetiform
  • Variable lesion types similar to pemphigoid or epidermolysis bullosa acquisita
  • Classic presentation – “string of pearls” lesion consisting of grouped vesicles
  • Involvement of oral mucosa – common
    • Ocular involvement – indistinguishable from ocular cicatricial pemphigoid
  • May exhibit severe pruritus
  • Perineal and perioral involvement common in children
  • Association with vancomycin and other drug exposure in drug-induced cases

Treatment

  • Dapsone
  • Immunosuppressives – prednisone therapy; however, this disease is less responsive to prednisone than pemphigoid
Tests generally appear in the order most useful for common clinical situations. Click on number for test-specific information in the ARUP Laboratory Test Directory.

Cutaneous Direct Immunofluorescence, Biopsy 0092572
Method: Direct Immunofluorescence

Recommended Use 

Order concurrently with serum antibody testing and fixed tissue histopathology for assessment of patient with pruritic, urticarial, blistering and/or erosive disorders, including possible pemphigoid and pemphigoid variants, pemphigus and pemphigus subtypes, dermatitis herpetiformis, epidermolysis bullous acquisita, porphyria, and pseudoporphyria

Order concurrently with fixed tissue histopathology for assessment of patient with inflammatory, immune-mediated cutaneous disease, including possible lupus and lupus variants, vasculitis, drug reactions, lichen planus and lichenoid reactions

For skin involvement, biopsy perilesional skin

For mucous membrane involvement, biopsy nonlesional mucosa

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

May be inaccurate if tissue not taken from correct perilesional location; specimen must have epidermis/epithelium and basement membrane zone (BMZ)

Concurrent serum testing helpful to characterize basement membrane zone antibody localization

Tissue must be submitted in Michel’s or Zeus medium; this test cannot be performed on formalin-fixed tissue

Follow-up 

Initial concurrent and repeat serum testing with pemphigoid panel is the most sensitive for diagnosis, for determining antibody profiles, and for following disease activity

Patients with indeterminate results should have repeat DIF biopsy

Patients with changing clinical features should have repeat DIF biopsy because antibody profiles may change over time

Pemphigoid Antibody Panel - Epithelial Basement Membrane Zone Antibodies, IgG and IgA, BP180 and BP230 Antibodies, IgG 0092001
Method: Enzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody

Recommended Use 

Preferred antibody panel for initial diagnostic assessment and disease monitoring in pemphigoid, epidermolysis bullosa acquisita, and linear IgA bullous dermatosis

Panel components include IgG and IgA epithelial BMZ antibodies and IgG bullous pemphigoid BP180 & 230 antigens

To order individual component tests, refer to antibody testing for IgG BMZ, IgA BMZ, and/or IgG bullous pemphigoid BP180 & 230 antigens

To screen for pemphigoid along with other possible immunobullous diseases, order concurrently with the pemphigus antibody panel  IgG collagen type VII antibody, AND perilesional skin biopsy for direct immunofluorescence

Concurrent perilesional skin biopsy for DIF is important for diagnosis because of increased sensitivity (85-100% of pemphigus, pemphigoid, linear IgA disease, epidermolysis bullosa acquisita, and dermatitis herpetiformis cases are positive)

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

Clinical correlation is necessary because the incidence of false-positives, although rare, increases with age

Because of clinical overlap among immunobullous diseases and similar names, pemphigoid testing may be confused with pemphigus testing and inadvertently misordered

Follow-up 

Use pemphigoid panel or epithelial IgA basement membrane zone IgA antibody tests to monitor pemphigoid disease activity and response to therapy

Repeat pemphigoid panel for indeterminate results and/or continuing clinical consideration of linear IgA disease

Pemphigus Antibody Panel - Epithelial Cell Surface Antibodies and Desmoglein 1 and Desmoglein 3 Antibodies, IgG 0090650
Method: Enzyme-Linked Immunosorbent Assay/Indirect Fluorescent Antibody

Recommended Use 

Preferred panel for initial assessment and disease monitoring in IgG-variant pemphigus

Panel components include antibody testing for IgG epithelial cell surface and IgG desmoglein 1 and 3; to order individual component tests, refer to epithelial skin antibody and/or desmoglein 1 and 3 antibodies in pemphigus, IgG

To screen for pemphigus along with other possible immunobullous diseases, order concurrently with antibody panel test for pemphigoid, IgG collagen type VII antibody, AND perilesional skin biopsy for direct immunofluorescence (DIF)

Concurrent perilesional skin biopsy for DIF is important for diagnosis because of increased sensitivity (85-100% of pemphigus, pemphigoid, linear IgA disease, epidermolysis bullosa acquisita, and dermatitis herpetiformis cases are positive)

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

Clinical correlation is necessary because cell surface antibodies by IFA, usually in low titers, may be found in normal individuals (possible blood group reactivity) or in patients with fungal infections, burns, drug reactions, and other dermatoses, including other immunobullous diseases

Because of clinical overlap among immunobullous diseases and similar names, pemphigoid testing may be confused with pemphigus testing and inadvertently misordered

Testing for IgG pemphigus antibody types (most common) also may be confused with IgA pemphigus testing (rare disorder)

Follow-up 

Use pemphigus panel to monitor pemphigus disease activity; use relevant tests to monitor other immunobullous disease activity

Repeat pemphigus panel for indeterminate results and/or continuing clinical consideration of immunobullous disease

Tissue Transglutaminase (tTG) Antibody, IgA with Reflex to Endomysial Antibody, IgA by IFA 0050734
Method: Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody

Recommended Use 

Use along with pemphigoid and pemphigus panel tests and epidermal transglutaminase antibody, IgA, or use with epithelial skin antibody and epidermal transglutaminase antibody, IgA testing to initially diagnose and discriminate among the immunobullous skin diseases in patients suspected or known to have any type of immunobullous disease

Reflex pattern – if tTG IgA is ≥4 U/mL units, then EMA IgA by IFA testing will be added

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

Does not detect IgA or other basement membrane zone antibodies that characterize linear IgA diseases (linear IgA bullous dermatosis, chronic bullous disease of childhood) or mixed immunobullous disease

Epithelial Basement Membrane Zone Antibody IgA 0092057
Method: Indirect Immunofluorescence
(Indirect Fluorescent Antibody)

Recommended Use 

Assess and monitor patient with linear IgA disease, including linear IgA bullous dermatosis and positive IgA BMZ antibodies, either epidermal (roof) pattern or dermal (floor) pattern

Consider ordering concurrently with IgG antibody testing for epithelial BMZ, bullous pemphigoid (BP180 & 230) antigens, and/or collagen type VII

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

Although helpful in screening for immunobullous disease, not as sensitive as combination of pemphigus and pemphigoid panels

Clinical correlation necessary because incidence of false positives, although rare, increases with age

Specific for IgA BMZ antibodies found in linear IgA disease and will not detect IgG BMZ antibodies found in pemphigoid and epidermolysis bullosa acquisita or cell surface antibodies found in pemphigus

Follow-up 

Use epithelial IgA BMZ IgA antibody or pemphigoid panel tests to monitor linear IgA disease activity and response to therapy; use relevant tests to monitor other immunobullous disease activity

Repeat epithelial IgA basement membrane zone IgA antibody or pemphigoid panel for indeterminate results and/or continuing clinical consideration of linear IgA disease

Epithelial Skin Antibody 0090299
Method: Indirect Immunofluorescence
(Indirect Fluorescent Antibody)

Recommended Use 

General screen for immunobullous diseases

Test includes IgG and IgA BMZ antibodies (pemphigoid, epidermolysis bullosa acquisita, linear IgA disease) and IgG and IgA cell surface antibodies (IgG and IgA pemphigus subtypes)

Consider ordering concurrently with IgG bullous pemphigoid (BP180 & 230) antigens for suspected pemphigoid and/or IgG desmoglein 1 and 3 antibodies for suspected pemphigus

For more sensitive and specific testing for pemphigoid or pemphigus, refer to antibody panels for pemphigus or pemphigoid

Refer to Immunobullous Skin Diseases Testing algorithm

Limitations 

Does not include testing for antibodies to target pemphigoid antigens, BP180 and BP230, or to target pemphigus antigens desmoglein 1 and 3 which may be more sensitive diagnostic markers in some cases (levels correlate with disease activity)

Although helpful in screening for immunobullous disease, test is not as sensitive as combination of pemphigus and pemphigoid panels

Follow-up 

Use epithelial skin antibody test or both pemphigoid and pemphigus panels to follow patients with changing clinical features because antibody profiles may change over time

General References

Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev. 2014; 13(4-5): 482-9. PubMed

Dilling A, Rose C, Hashimoto T, Zillikens D, Shimanovich I. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol. 2007; 34(1): 1-8. PubMed

Fortuna G, Marinkovich P. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012; 30(1): 38-50. PubMed

Hull C, Zone J. Dermatitis herpetiformis and linear IgA bullous dermatosis, Ch 31. In Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology, 3rd ed. Waltham, MA: Elsevier Inc, 2012.

Patrício P, Ferreira C, Gomes MM, Filipe P. Autoimmune bullous dermatoses: a review. Ann N Y Acad Sci. 2009; 1173: 203-10. PubMed

Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010; 10(2): 84-9. PubMed

Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Dermatol Clin. 2011; 29(3): 453-8, ix. PubMed

Medical Reviewers

Leiferman, Kristin M., MD, Consultant, Immunodermatology at ARUP Laboratories; Co-Director, Immunodermatology Laboratory, Professor of Dermatology, University of Utah

Last Update: July 2017